Feng Wang
Sun Yat-Sen University Cancer Center · Sun Yat-sen Univesity Cancer Center · Beijing Chaoyang Hospital, China
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Feng Wang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:56 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07621497 · FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)Sun Yat-sen University · not yet recruiting · Metastatic Colorectal Cancer (CRC) · principal investigator
- Ph2NCT07518602 · Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine CarcinomaSun Yat-sen University · recruiting · Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) · principal investigator
- N/ANCT07326072 · The Study of ENB With Ultra-thin Cryobiopsy in the Diagnosis of Peripheral Pulmonary NodulesBeijing Chao Yang Hospital · enrolling by invitation · Diagnosis · study chair
- N/ANCT07144995 · MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ AdenocarcinomaSun Yat-sen University · not yet recruiting · Advanced Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Fruquintinib · principal investigator
- Ph1/Ph2NCT06947226 · A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid TumorsMabwell (Shanghai) Bioscience Co., Ltd. · not yet recruiting · Solid Tumors · principal investigator
- Ph2NCT06718205 · Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell CarcinomaThe First Affiliated Hospital of Zhengzhou University · recruiting · Esophageal Cancer · principal investigator
- Ph1NCT06500052 · A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid TumorsSichuan Baili Pharmaceutical Co., Ltd. · recruiting · Esophageal Cancer, Gastric Cancer, Pancreatic Cancer · principal investigator
- Ph2NCT06439550 · Adjuvant Treatment With Serplulimab,Trastuzumab and SOX in the HER-2 Positive GC/GEJCThe First Affiliated Hospital of Zhengzhou University · not yet recruiting · HER2-positive Gastric Cancer · principal investigator
- N/ANCT06431620 · Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid CancerNanjing First Hospital, Nanjing Medical University · recruiting · Recombinant Human Thyroid Stimulating Hormone · principal investigator
- N/ANCT06431360 · Effect of Strontium-90 Brachytherapy Combined With Hyperthermia in the Treatment of KeloidNanjing First Hospital, Nanjing Medical University · unknown · Keloid · study director
- N/ANCT06261762 · Hard and Soft Tissue Dimensional Change After Consecutive Extractions and Unassisted Socket Healing in the Esthetic ZoneShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · unknown · Wound Heal · principal investigator
- N/ANCT06054789 · Clinical Study on 68Ga-PSMA-33 for PET/CT Imaging of Prostate CancerNanjing First Hospital, Nanjing Medical University · unknown · Prostate Cancer · study director
- Early Ph1NCT06050239 · Study of 177Lu-PSMA-0057 in Metastatic Prostate CancerNanjing First Hospital, Nanjing Medical University · unknown · Metastatic Prostate Cancer · study director
- Ph2NCT06044350 · A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum DisordersBio-Thera Solutions · active not recruiting · Optic Neuromyelitis Spectrum Disease · principal investigator
- Ph2NCT05896787 · Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)The First Affiliated Hospital of Zhengzhou University · unknown · Esophageal Squamous Cell Carcinoma · principal investigator
- N/ANCT05867589 · Study of Novel PET Tracer Gallium [68Ga]/ Fluorine [18F] -FAPI-04 in the Diagnosis of Cardiovascular DiseasesNanjing First Hospital, Nanjing Medical University · unknown · Myocardial Fibrosis · study director
- Ph2NCT05738434 · Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCCThe First Affiliated Hospital of Zhengzhou University · recruiting · Esophageal Cancer by AJCC V8 Stage · principal investigator
- Ph1/Ph2NCT05330065 · A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural EffusionThe First Affiliated Hospital of Zhengzhou University · unknown · Malignant Pleural Effusion · principal investigator
- Ph2NCT05241899 · A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) CancerThe First Affiliated Hospital of Zhengzhou University · unknown · Gastric Cancer · principal investigator
- Ph3NCT05049681 · Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous CellFeng Wang · unknown · Esophageal Cancer · principal investigator
- N/ANCT05048810 · Clinical Application of 68Ga-DOTA-NT-20.3 in the Early Diagnosis of Pancreatic Ductal AdenocarcinomaNanjing First Hospital, Nanjing Medical University · completed · Pancreatic Ductal Adenocarcinoma · study director
- Early Ph1NCT05043675 · Clinical Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease PatientsNanjing First Hospital, Nanjing Medical University · unknown · Alzheimer Disease · study director
- Ph2NCT04984018 · Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 BlockadeThe First Affiliated Hospital of Zhengzhou University · unknown · Esophageal Squamous Cell Carcinoma · principal investigator
- Ph2NCT04888403 · Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell CarcinomaThe First Affiliated Hospital of Zhengzhou University · unknown · Locally Advanced Esophageal Squamous Cell Carcinoma · principal investigator
- N/ANCT04654403 · Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell CancerThe First Affiliated Hospital of Zhengzhou University · unknown · Esophageal Cancer · principal investigator
- Ph2NCT04533490 · A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell CarcinomaThe First Affiliated Hospital of Zhengzhou University · unknown · Resectable Esophageal Squamous Cell Carcinoma · principal investigator
- Ph2NCT04514835 · A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCCThe First Affiliated Hospital of Zhengzhou University · unknown · Esophageal Squamous Cell Carcinoma · principal investigator
- Early Ph1NCT04185350 · Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of InsulinomaNanjing First Hospital, Nanjing Medical University · unknown · Insulinoma · study director
- Ph2NCT04180007 · Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid CancersNanjing First Hospital, Nanjing Medical University · unknown · Thyroid, Metastasis, Apatinib · study director
- Ph2NCT03917966 · The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCCThe First Affiliated Hospital of Zhengzhou University · unknown · Locally Advanced Esophageal Squamous Cell Carcinoma · principal investigator
- Ph2NCT03817658 · A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCCThe First Affiliated Hospital of Zhengzhou University · unknown · Esophageal Squamous Cell Carcinoma · principal investigator
- Ph2NCT03810339 · Toripalimab(JS001) as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid TumorsSun Yat-sen University · recruiting · Solid Tumor, Advanced Cancer · principal investigator
- Ph2NCT03766178 · Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell CarcinomaThe First Affiliated Hospital of Zhengzhou University · unknown · Esophageal Squamous Cell Carcinoma · principal investigator
- Ph2NCT03736863 · A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell CarcinomaThe First Affiliated Hospital of Zhengzhou University · unknown · Esophageal Cancer · principal investigator
- Ph2NCT03387904 · Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell CarcinomaThe First Affiliated Hospital of Zhengzhou University · unknown · Esophageal Squamous Cell Carcinoma · principal investigator
- N/ANCT02720003 · A Single Arm Trial Evaluating the BARD Lutonix Drug-Coated Balloon (LTX DCB) for Treatment of Femoropopliteal ArteriesC. R. Bard · completed · Femoral Artery Stenosis, Femoral Artery Occlusion, Stenosis of Popliteal Arteries · principal investigator
- N/ANCT01998204 · Requirement of Propofol for Induction of Unconsciousness in Patients With Parkinson's DiseaseChanghai Hospital · completed · Parkinson's Disease · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 45 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in colorectal cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:56 UTC. The ranking covers the 200 most relevant of 53 PubMed records, and a shared surname and initials can bring in a namesake. All 53 on PubMed
- The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients.Med Oncol · 2014239 citationsRCR 8.3
- Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial.Nat Med · 2024171 citationsRCR 18.7
- Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis.Cell Rep Med · 2021154 citationsRCR 7.3
- Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study.Lancet Gastroenterol Hepatol · 2023136 citationsRCR 10.3
- Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial.Cancer Cell · 202488 citationsRCR 8.1
- Selenium Supplementation for Prevention of Colorectal Adenomas and Risk of Associated Type 2 Diabetes.J Natl Cancer Inst · 201678 citationsRCR 3.4
- 73 citationsRCR 1.9
- 54 citationsRCR 3.9
- Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial.J Natl Cancer Inst · 201646 citationsRCR 1.4
- 45 citationsRCR 2.7